Antibody-drug conjugates (ADCs) are revolutionizing cancer treatment and heralding in a new era of targeted therapies. Although ADCs have been in development since the 1980s, recent advances in antibody engineering, linker stability, and payload technologies have reignited interest and investment in this powerful drug class.
Watch this webinar to hear from clinical operations and medical experts as they share real-world case studies and practical strategies for navigating the complex and competitive ADC clinical trial landscape. Designed for teams planning their first ADC study or optimizing ongoing programs, this session offers practical and actionable insights.
The panel of experts in this webinar includes:
- Andrew Zupnick, PhD, Vice President, Oncology Drug Development, Catalyst Oncology (Moderator)
- Udayan Guha, MD, PhD, Chief Medical Officer, NextCure
- Stephanie Kordahi, MS, Senior Director, Clinical Operations, NextCure
- Shodeinde (Deinde) Coker, MD, MSc, Executive Medical Director, Biohaven
